Alopecia is listed as an adverse reaction in the Zepbound (weight management) UK SmPC, but not in the Mounjaro (type 2 diabetes) SmPC
Medicare Part D can cover Mounjaro when prescribed for type 2 diabetes but cannot cover it for weight loss
Importantly, future studies on tirzepatide should specifically focus on sex differences, the role of reproductive status, and other major disease modifiers on treatment response [54, 55, 78, 79]
Semaglutide For type 2 diabetes, it is administered subcutaneously once a week, typically starting with a low dose and adjusted based on individual response
While the exact mechanism is unclear, these side effects could arise from changes in metabolism, hydration, or electrolyte balance caused by the medication